Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN W CODEINE versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN W CODEINE versus QOLIANA.
PHENERGAN W/ CODEINE vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative with H1 receptor antagonist activity, antiemetic, and sedative properties. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting pain transmission and causing cough suppression.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
10 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4 to 6 hours, not to exceed 60 mL (codeine 60 mg) per day.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Promethazine: 9-16 h; codeine: 3.5 h (terminal), prolonged in renal impairment (up to 18 h).
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: 70% (codeine as unchanged and metabolites, ~10% as morphine-3-glucuronide, <10% as morphine); biliary/fecal: 30% (promethazine as sulfoxides and glucuronides).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist